Step 1 of 2
Downloadable slides on the diagnosis and management of H3 K27–altered diffuse midline glioma (DMG), including molecular testing strategies, clinical characteristics, and emerging treatment approaches. The slides review clinical efficacy and safety data supporting dordaviprone for recurrent H3 K27M–mutant DMG following prior therapy, its mechanism of action, and practical considerations for treatment initiation, dosing, adverse event management, QTc monitoring, and drug interactions. Evidence from ongoing studies of targeted therapies, CAR T-cell therapies, oncolytic viruses, and other investigational approaches is also highlighted, along with strategies for postradiation treatment sequencing, clinical trial referral, and multidisciplinary care coordination to support individualized treatment decisions in pediatric and adult patients.